Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

WCG

- PMLiVE

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19

- PMLiVE

Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk

REGEN-COV reduced the risk of symptomatic infections by 81% in a phase 3 prevention trial

Lucid Group Bolster its Senior Leadership Team

Lucid Group are delighted to welcome Jo Troman to the role of Managing Partner for team Origins. Jo has a wealth of industry experience from both client and agency sides....

Lucid Group Communications Limited

Roche Basel Switzerland

EU authorises Roche’s spinal muscular atrophy treatment Evrysdi

First SMA treatment approved in the EU that can be taken at home

- PMLiVE

Roche, Regeneron’s COVID-19 antibody cocktail cuts hospitalisation or death by 70%

Phase 3 trial is evaluating the therapy in high-risk non-hospitalised patients with COVID-19

Roche Basel Switzerland

Roche’s Tecentriq yields positive data in early stage NSCLC

PD-L1 inhibitor improved disease-free survival in phase 3 IMpower010 study

- PMLiVE

A Stellar Start to 2021 for Lucid Group

It’s been a stellar start to 2021 for Lucid Group, which has welcomed 38 new starters into the company since the beginning of the year. These include 15 Client Services...

Lucid Group Communications Limited

- PMLiVE

Roche buys GenMark for $1.8bn to bolster diagnostics portfolio

Swiss pharma company will gain respiratory pathogen panels to strengthen its COVID-19 testing capabilities

- PMLiVE

Healthcare agency Page & Page and Partners welcomes wave of new talent

Page & Page and Partners has welcomed six new joiners across its Creative and Client Services teams.

Page & Page and Partners

Onyx Health Targets Digital Growth with New Executive Director

Healthcare marketing communications agency Onyx Health have appointed Trevor Pill as their new Executive Director

Onyx Health

- PMLiVE

Roche’s anti-inflammatory drug reduces deaths in hospitalised COVID-19 patients

Tocilizumab, marketed as Actemra/RoActemra, also reduced time spent in hospital in RECOVERY trial

Roche Basel Switzerland

Roche’s diagnostic business sales offer a bright spot in Q4

Company's pharmaceutical division sales slipped due to biosimilar competition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links